摘要
目的了解普罗布考对心血管病高风险人群冠状动脉事件的影响。方法通过阅读芬兰赫尔辛基大学在20世纪70年代初进行的心血管病多危险因素干预试验发表的论文,从中提取普罗布考治疗的有关结局事件信息,整理后用于分析普罗布考对冠状动脉事件的影响。结果普罗布考特别是与安妥明合用时可显著降低高密度脂蛋白胆固醇水平,未加用普罗布考各用药组(除利尿剂组外)实际冠状动脉事件发生数高于预测值,而加用普罗布考后降低冠状动脉事件的发生。使用普罗布考和使用其他药物(不用普罗布考)时的5年累积冠状动脉事件发生率不同(1.0%比3.6%,P=0.040)。考虑各不同药物组的影响以后,加用普罗布考与冠状动脉事件发生之间的联系有统计学意义(P=0.008),相对危险度估计值为0.186,其95%可信区间为0.053～0.656。结论普罗布考虽然降低高密度脂蛋白胆固醇浓度,但对其他药物难以控制血脂者合并使用普罗布考仍然可能改善用药者发生冠状动脉事件的风险。
Aim To a review the prevention with probucol in subjects with high risk of cardiovascular disease. Methods The relevant information on the outcome events of probucol treatment was extracted from papers of Multifactorial Primary Prevention Trial of Vascular Disease in Finland to analyze the effect of probucol on coronary events. Resuits Probucol, especially when combined with clofibrate, markedly reduced high density lipoprotein cholesterol. The number of coronary events was higher than predictive values in those men who had been treated with clofibrate and betablockers but it is lower with probucol added. Five years cumulative incidence of coronary events is different in group with probucol added and without probucol added （ 1.0% vs 3.6% ,P = 0. 040 ）. Taking into account the impact of different drugs, there were significant association between probucol and coronary events （RR was 0. 186, 95% CI was 0.053 to 0. 656, P = 0.008）. Conclusion Although probucol decreased high density lipoprotein cholesterol levels, if cholesterol levels remained high, other drugs combined with probucot can stiu reduce coronary events in high risk subjects.
出处
《中国动脉硬化杂志》
CAS
CSCD
2008年第10期763-766,共4页
Chinese Journal of Arteriosclerosis
基金
上海市重点学科建设项目资助(B118)
